POINT Biopharma Global Inc.

The momentum for this stock is not very good. POINT Biopharma Global Inc. has good growth characteristics. POINT Biopharma Global Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in POINT Biopharma Global Inc. .

News

Lilly Completes Acquisition of POINT Biopharma

PR Newswire Lilly Completes Acquisition of POINT Biopharma Lilly Completes Acquisition of POINT Biopharma PR Newswire INDIANAPOLIS, Dec. 27, 2023 INDIANAPOLIS, Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company...\n more…

POINT Biopharma Global Rating Adjustment: Hold Recommendation Following Shareholder Dynamics and Acquisition Prospects

TipRanks Financial Blog no summary\n more…

Why POINT Biopharma Global Is At Least A Hold On Disappointing Readout

SeekingAlpha Why POINT Biopharma Global Is At Least A Hold On Disappointing Readout...\n more…

Why is Prostate Cancer Focused Lantheus Stock Trading Lower Today?

Benzinga Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic castration-res\n more…

Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

Globe Newswire Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS)BEDFORD, Mass.and INDIANAPOLIS, Dec. 18, 2023 (GLOBE...\n more…

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023

PR Newswire Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 PR Newswire INDIANAPOLIS, Dec. 18, 2023 INDIANAPOLIS...\n more…